ArticleClinical case reports2026
Contezolid in the Treatment of Multidrug-Resistant Tuberculous Meningitis: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant tuberculous meningitis (MDR-TBM) has a high mortality rate, and treatment options are limited. Linezolid is recommended for refractory cases but often causes intolerable adverse reactions such as peripheral neuropathy. Contezolid, a novel oxazolidinone, has shown better safety profiles in preclinical and early clinical studies. Here we report a 33-year-old male with MDR-TBM who developed progressive peripheral neuropathy after 6 months of a linezolid-containing regimen. Linezolid was discontinued, but cerebrospinal fluid (CSF) parameters remained abnormal. Contezolid was initiated in July 2023. Within 3 months, the patient's headache and blurred vision resolved; after 5 months of treatment, CSF pressure normalized, protein decreased from 1570 to 501 mg/L, and glucose returned to normal range. No adverse reactions occurred during contezolid therapy, and clinical improvement was sustained through 24-month follow-up. This case suggests contezolid may be a safe and effective alternative to linezolid for MDR-TBM patients with drug intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.